Prenen, Hans <br/><br/>
Phospholipase C gamma 1 (PLCG1) R707Q mutation is counterselected under targeted therapy in a patient with hepatic angiosarcoma.  [electronic resource] 

 -  Oncotarget  Nov 2015 
 - 36418-25 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.5503  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--therapeutic use<br/>Cytogenetics<br/>Female<br/>Hemangiosarcoma--drug therapy<br/>Humans<br/>Indoles--therapeutic use<br/>Liver Neoplasms--drug therapy<br/>Middle Aged<br/>Mutation<br/>Phospholipase C gamma--genetics<br/>Pyrroles--therapeutic use<br/>Signal Transduction<br/>Sunitinib